PROCEPT BioRobotics
14
1
5
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
29%
2 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
WATER IV Prostate Cancer
Role: lead
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
Role: lead
WATER III: Aquablation vs. Transurethral Laser Enucleation of Large Prostates (80 - 180mL) in Benign Prostatic Hyperplasia
Role: collaborator
PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
Role: lead
AQUABEAM® Robotic System and Ultrasound Accessories
Role: collaborator
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
Role: lead
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Role: lead
UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
Role: lead
Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III
Role: lead
Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
Role: lead
French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
Role: lead
AQUABEAM India Study for the Treatment of Benign Prostatic Hyperplasia
Role: lead
Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia
Role: lead
Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia II
Role: lead
All 14 trials loaded